Neutrophil-Mediated Delivery of Dexamethasone Palmitate-Loaded Liposomes Decorated with a Sialic Acid Conjugate for Rheumatoid Arthritis Treatment.
- Resource Type
- Article
- Authors
- Hu, Ling; Luo, Xiang; Zhou, Songlei; Zhu, Jingyang; Xiao, Mingyue; Li, Cong; Zheng, Huangliang; Qiu, Qiujun; Lai, Chaoyang; Liu, Xinrong; Deng, Yihui; Song, Yanzhi
- Source
- Pharmaceutical Research. Jul2019, Vol. 36 Issue 7, p1-15. 15p. 2 Diagrams, 1 Chart, 12 Graphs.
- Subject
- *LIPOSOMES
*SIALIC acids
*RHEUMATOID arthritis
*THERAPEUTICS
*EXPERIMENTAL arthritis
*DRUG delivery systems
- Language
- ISSN
- 0724-8741
Purpose: The aim of this research was to design dexamethasone palmitate (DP) loaded sialic acid modified liposomes, with the eventual goal of using peripheral blood neutrophils (PBNs) that carried drug-loaded liposomes to improve the therapeutic capacity for rheumatoid arthritis (RA). Methods: A sialic acid – cholesterol conjugate (SA-CH) was synthesized and anchored on the surface of liposomal dexamethasone palmitate (DP-SAL). The physicochemical characteristics and in vitro cytotoxicity of liposomes were evaluated. Flow cytometry and confocal laser scanning microscopy were utilized to investigate the accumulation of liposomes in PBNs. The adjuvant-induced arthritis was adopted to investigate the targeting ability and anti-inflammatory effect of DP loaded liposomes. Results: Both DP-CL and DP-SAL existed an average size less than 200 nm with remarkably high encapsulation efficiencies more than 90%. In vitro and in vivo experiments manifested SA-modified liposomes provided a reinforced accumulation of DP in PBNs. As well, DP-SAL displayed a greater degree of accumulation in the joints and a stronger anti-inflammatory effect in terms of RA suppression. Conclusions: SA-modified liposomal DP was a promising candidate for RA-targeting treatment through the neutrophil-mediated drug delivery system. [ABSTRACT FROM AUTHOR]